Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.
Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.
复制标题
DOI：
10.3748/wjg.14.1321
复制
发表时间：
2008-03
影响因子：
4.3
通讯作者：
Yanxia Mi;Y. Long;Yun-chun Li
中科院分区：
文献类型：
--
作者：
Yanxia Mi;Y. Long;Yun-chun Li
一百多年来，病毒一直被认为能够杀死肿瘤细胞。目前，人们仍在研究和构建更适合治疗不同恶性肿瘤的溶瘤病毒。尽管广泛的研究表明，单纯疱疹病毒1型(HSV-1)是最具潜力的溶瘤病毒，但基于1型单纯疱疹病毒载体的治疗仍存在生物安全性和风险管理问题。因此，研究人员引入了用放射性核素标记HSV-1突变株治疗癌症的新想法，将放射性核素和溶瘤病毒疗法结合起来。本文简要综述了溶瘤病毒杀伤肿瘤细胞的现状和机制，讨论了HSV-1和HSV-1衍生载体在肿瘤治疗中的应用，论证了放射性核素标记HSV-1突变体用于肿瘤治疗的可行性和前景。
For over one hundred years, viruses have been recognized as capable of killing tumor cells. At present, people are still researching and constructing more suitable oncolytic viruses for treating different malignant tumors. Although extensive studies have demonstrated that herpes simplex virus type 1 (HSV-1) is the most potential oncolytic virus, therapies based on herpes simplex virus type 1 vectors still arouse bio-safety and risk management issues. Researchers have therefore introduced the new idea of treating cancer with HSV-1 mutants labeled with radionuclides, combining radionuclide and oncolytic virus therapies. This overview briefly summarizes the status and mechanisms by which oncolytic viruses kill tumor cells, discusses the application of HSV-1 and HSV-1 derived vectors for tumor therapy, and demonstrates the feasibility and prospect of HSV-1 mutants labeled with radionuclides for treating tumors.